Stay updated with breaking news from Subgroup Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The...
/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...
/PRNewswire/ -- Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review...
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.